BrightHeart vs Truvian Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in prenatal ultrasound. Distributed via GE HealthCare Voluson platform.
About
BrightHeart is a medical AI company developing prenatal diagnostic tools for detecting congenital heart defects (CHD) — the most common birth defect globally — through standard obstetric ultrasound. The company raised €11 million ($12 million) in Series A financing in January 2026 and achieved five FDA clearances in 2025 ahead of US commercial launch, with distribution through GE HealthCare's Voluson ultrasound platform.
Truvian Health received FDA 510(k) clearance for its TruVerus benchtop blood analyzer in Dec 2025; raised $74M in July 2024 and is partnering with Shoppers Drug Mart for commercial rollout.
About
Truvian Health is a San Diego-based medical diagnostics company developing an automated benchtop blood testing platform that delivers lab-accurate results from a few drops of blood in under 30 minutes — without requiring trained laboratory personnel. The company's flagship product, TruVerus, combines multiple blood test modalities into a single compact analyzer designed for point-of-care settings such as physician offices, clinics, urgent care centers, and long-term care facilities that lack on-site labs.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.